Compare BEEP & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEEP | RNTX |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.3M | 80.7M |
| IPO Year | 2021 | N/A |
| Metric | BEEP | RNTX |
|---|---|---|
| Price | $1.59 | $0.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.50 | ★ $10.00 |
| AVG Volume (30 Days) | 47.7K | ★ 609.8K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,075,000.00 | N/A |
| Revenue This Year | $5.77 | N/A |
| Revenue Next Year | $22.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.52 | $0.85 |
| 52 Week High | $4.67 | $2.18 |
| Indicator | BEEP | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.06 | 45.01 |
| Support Level | N/A | $0.85 |
| Resistance Level | $2.34 | $1.33 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 6.40 | 54.47 |
Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.